DUBLIN, December 7, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/bxqjkr/world) has announced the addition of the "World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020" report to their offering.
According to the new report title "World Castration-Resistant Prostate Cancer (CRPC) Therapeutics - Market Opportunity and Forecast, 2014-2020", the global CRPC therapeutics market would generate a revenue of $9.5 billion by 2020, registering a CAGR of 9.1% from 2015 to 2020. Hormonal therapy segment spearheads among all the therapy types, governing around 4/5th of the global market value in 2014 and would sustain its market position throughout 2020.
The global CPRC therapeutics market has witnessed high growth in the past few years and would continue to grow at a consistent pace due to the high unmet clinical need associated with the disease. Large amount of drugs in pipeline, augmented patient awareness and untapped nmCRPC space would largely drive the market growth during the forecast period. On the other hand, introduction of novel treatments would be difficult as long as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require an improvement in overall survival period. Moreover, lack of differentiation in mechanism of action among the approved and novel agents along with factors such as premium pricing and uncertain reimbursement policies would hinder the market growth during the analysis period.
The market would gain traction in the emerging countries of Asia-Pacific and third-world countries such as Africa and Latin America. Asia Pacific and LAMEA region would collectively constitute around 1/3rd of the overall market by 2020. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards healthcare and growing awareness about prostate cancer would be the prime reasons responsible for the impressive market growth in these regions. The market growth would mainly rely on the novel breakthrough treatments with improved overall survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
- AstraZeneca PLC
- Eli Lily and Company
- F. Hoffman
- Johnson & Johnson
- La Roche AG
- Merck & CO.
Chapter: 1 INTRODUCTION
Chapter: 2 EXECUTIVE SUMMARY
Chapter: 3 MARKET OVERVIEW
Chapter: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION
Chapter: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS
Chapter: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY
Chapter: 7 COMPANY PROFILE
For more information visit http://www.researchandmarkets.com/research/bxqjkr/world
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SOURCE Research and Markets